Fingolimod (FTY720) As an Anti-Multiple Sclerosis Oral Ultimate Therapy

Sara T. Alrashood1*, Fadilah S. Aleanizy2, Fulwah Alqahtani2, Ahad Abushal3, Noor AlSalama3 and Ghada S. Hassan4

1Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O.Box 2457, Riyadh 11451, Saudi Arabia.
2Department of Pharmaceutics, College of Pharmacy, King Saud University, P.O.Box 2457, Riyadh 11451, Saudi Arabia.
3College of Pharmacy, King Saud University, P.O.Box 2457, Riyadh 11451, Saudi Arabia.
4Department of Medicinal Chemistry, Faculty of Pharmacy, Mansoura University, P.O.Box 35516, Mansoura, Egypt.

DOI: http://dx.doi.org/10.13005/bbra/1770

(Received: 12 March 2015; accepted: 28 April 2015)

Multiple Sclerosis (MS) is a chronic progressive autoimmune disease. It has complex symptoms and challenges. Patients suffer the most from the inconvenience and intolerability till the old injectable disease modifying therapies. Therefore our research is highlighting the scoop on the newly available treatment using the oral therapies proceeding from their chemical nature and structure to prove their superiority to the traditional ones in controlling MS progression. This can lead to an improvement in life quality for MS patients with the enhanced tolerability for oral drugs that is best achieved by using Fingolimod that is considered as the first approved oral drug for this disease.

Key words: Multiple Sclerosis (MS), Autoimmune disease, Fingolimod, Therapy.
cognitive dysfunction, fatigue, numbness, and pain. Quality of life may be further reduced by mood disorders and limitations in social functioning. Considering the line of treatment, multiple sclerosis is untreatable, only several attempts for function improvement after an attack with prevention of further attacks.

On the other hands, not only these drugs have moderate effect but also they can have adverse effects in addition to the poor toleration produced. Prediction of the long-term use is very difficult, good outcomes appear mostly in women, and especially who has early development of the disease early in life, in addition to those with a relapsing course, and finally those who experienced low number of attacks. Some expectations were discussed about the life-time of the patients over the unaffected ones, it was found that it is on average 5 to 10 years lower than healthy population. As mentioned before, there is no acceptable cure for this disease, only several therapies have proven to help improvement of the life style in tolerance the possible attacks. The primary aims of the used drugs are to return the normal function after a possible attack, in addition to the attempt to prevent further attacks, and finally trying to prevent the irreversible disability.

The usual therapy used during symptomatic attacks is the administration of high doses corticosteroids by intravenous route, such as methylprednisolone. Similarly, treatment with oral corticosteroids gives the same effect and safety profile. On the other hand, corticosteroid treatments appear to be ineffective in the long term recovery contrast for the short term therapy. Furthermore, treatment of attacks that do not respond to corticosteroids relies on the use of plasmapheresis. Other lines of treatments including Disease Modifying Therapies (DMTs) for Relapsing remitting multiple sclerosis or Progressive multiple sclerosis. In case of DMTs their efficacy is determined by the reduction of relapses rate and decreased accumulation of brain lesions on Magnetic Resonance Imaging (MRI). The First line of treatment includes Interferon a-IFNb-1b (betaferon, Extavia), or b-IFNb-1a (Avonex, Rebif), and Glatiramer acetate (GA) while the Second line involves the use of Natalizumab (Tysabri), Fingolimod (Gilenya), Triflunamide (Aubagio), and DimethyleFumarate (Tecfidera).

In September 2010, Fingolimod was approved as oral DMT for relapsing multiple sclerosis. It is a sphingosine-1-phosphate receptor (S1P) agonist a G-protein coupled receptor- binding to 4 of the 5 S1P receptor subtypes and acting as a functional antagonist. The drug is highly lipophilic but well absorbed orally regardless food and fatty meals (93% oral bioavailability). In vivo, it’s rapidly and reversibly phosphorylated by sphingosine kinase-2 to its active metabolite Fingolimod phosphate. Fingolimod is metabolized by (CYP4F2) giving low potential for drug-drug interactions as few numbers of drugs are metabolized by this enzyme.

It is used as one 0.5 mg oral capsule once daily. It is indicated as single DMT in highly active relapsing remitting MS; this group of patients include those who are treated with a beta-interferon but still suffer from high disease activity. These patients do not show any response to a full and adequate course of total one year of treatment using beta-interferon, and they still have had at least 1 relapse in the previous year while on therapy, and have at least 9 T2-hyperintense lesions in cranial MRI or at least 1 Gadolinium-enhancing lesion. A term “non-responder” is used for patients who remain unchanged or suffer from episodes of increased relapse rate or ongoing severe relapses, as compared to the previous year, in addition to patients who have 2 or more disabling relapses in one year named rapidly evolving severe relapsing remitting multiple sclerosis, and with 1 or more Gadolinium enhancing lesions or a significant increase in T2 lesion load as compared to a previous recent MRI. The objectives of this research is to conduct a case study in which the Fingolimod was used, collection of data and observation will lead to a conclusion that can be used for the future development and treatment regimen.

**MATERIALS AND METHODS**

A case study was conducted, using patients’ data on Fingolimod therapy and compare it with other patients’ data on Interferon (INF) therapy, for 6-12 months period of time,
and between age 20-40( years. All patients informed consent was obtained for using their data only, they required their names being blinded. The data was collected from three different sites, King Khalid University Hospital (KKUH), King Faisal Specialty Hospital (KFSH) both in Riyadh, and international MS clinic in Germany. The data collection was based on observing the patients for enhanced tolerability and adherence to regimen with decreased relapses rate, disability progression and improved lesions on MRI. The comparison is made between INFs and Fingolimod aiming for better MS patients’ Quality of life and to prove the superiority of oral DMTs to the injectable traditional ones. A close attention was paid for Fingolimod cardiotoxic side effects, macular edema, and other major side effects as well. Finally, synthesis of such drug involves scheme of a facile six-step beginning with readily available and inexpensive starting material (diethyl acetamidomalonate), that produces the hydrochloride salt of the drug in an acceptable yield. (scheme1)

![Scheme 1. Lab synthesis of Fingolimod HCl](image)

**RESULTS AND DISCUSSION**

Starting with the patients sample collected for the case study, 43% of the female patients started their therapy using Fingolimod while the rest of females switched from the treatment with interferons (INF) to the test drug. On the other hands, the male patients were classified into 3 groups: those that started with Fingolimod, other group switched from avonex to the test drug, and the final group switched from Rebif to the test drug(Fig.2 and 3).

A comparison was made between male and female patients under investigations, it appears that the percentage that switched from INF to fungolimod in females is much greater than those in male. On the other hands, the side effects of the drugs appeared in such a large percentage in males than females (Fig. 4).

According to the data obtained many of the side effects recorded lower percentage in interferon models than that of fingolimod ones, such as nausea, diarrhea and ALT increased. On the other hands, fingolimod recorded lower percentages in most concerning side effects such as influenza, depression and influenza-like sickness, in addition to very high percentage on the reduction of relapsing rate.

From the study obtained, some items were recommended to be monitored including

**Heart rate**

Bradycardia appears after the first dose

| Table 1. Summary of Efficacy Data From Pivotal Controlled Trials for Recently Developed Multiple Sclerosis Disease-Modifying Therapies |
|---------------------------------|-----------------|---------------|------------------|
| Characteristic                  | Fingolimod     | Teriflunomide  | Dimethyl fumarate |
| Brand name                      | Gilenya         | Aubagio        | Tecfidera        |
| Year approved                   | 2010            | 2012           | 2013             |
| Dose                            | 0.125 or 0.5 mg | 7 or 14 mg     | 240 mg           |
| Route                           | Oral            | Oral           | Oral             |
| Frequency                       | Daily           | Daily          | BID              |
| Relative Risk Reduction         | 54%             | 31%            | 51%-53%          |
| Absolute Risk Reduction         | 0.18            | 0.37           | 0.17             |
| Numbers needs to treat          | 2               | 5              | 6                |
and lasts for 6 hours. The mean decrease in heart rate was calculated at 6 hours after the first 0.5 mg dose and it was approximately 13 bpm. This disadvantage disappeared by continued dosing within 1 month.

**Infections**

Complete Blood Cell count (CBC) before starting therapy with Fingolimod. It reduces peripheral lymphocyte counts to 20%-30% of baseline. Treatment should not be initiated in patients with active acute or chronic infections. Coadministration of ketoconazole (an antifungal), a CYP4F2 inhibitor increases the area under the curve (AUC) of Fingolimod and its metabolite Fingolimod phosphate. This requires dosage adjustments (Table-1).

**Macular edema**

Ophthalmologic evaluation especially with diabetic patients should be performed before starting therapy with fingolimod and at 3 to 4 months after.

**Cautions must be considered with patients over 65 years.**

Patients with cardiovascular problems such as ischemic heart disease, or heart failure, who have type II second-degree, or third-degree AV block or sick sinus syndrome should not experience such medication, unless the patient has a functioning pacemaker.

No dose adjustment is needed in moderate-severe renal failure, or with hepatic impairment. In case of drug interruption first dose effect can reappear and it requires monitoring when the treatment is reinitiated.
CONCLUSION

Fingolimod is a promising oral agent for use in the treatment of relapsing forms of MS. It showed positive outcomes on phase 3 clinical trials and by that it captured the era on the oral MS therapy and it opened the gate for the drug design and discovery for designing more MS oral DMTs. Therefore, we synthesized Fingolimod-HCl and studied its chemical nature, and conducted our study using 6-12month patients data that showed a reduction in relapsing rate and MRI lesions, also a decreased risk of disability progression with enhanced overall patient quality of life in comparison with Interferons and other DMTs. Fingolimod therapy requires Careful patient selection and close monitoring that is necessary to avoid toxicities.

ACKNOWLEDGEMENTS

We thankfully appreciate Professor Ahmed AlRasheed for patients Data from MS clinic in Germany, Also the heads of King Khalid University Hospital (KKUH), and King Faisal Specialty Hospital (KFSH) and information center in Riyadh for the ease of access to patients’ data.

REFERENCES